TCIM
NBIX icon

TIAA CREF Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

TIAA CREF Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$46.2M Buy
524,465
+293,210
+127% +$24.5M 0.03% 427
2018
Q4 		$16.5M Sell
231,255
-95,643
-29% -$9.16M 0.01% 717
2018
Q3 		$40.2M Buy
326,898
+4,655
+1% +$528K 0.03% 506
2018
Q2 		$31.7M Buy
322,243
+14,425
+5% +$1.29M 0.02% 578
2018
Q1 		$25.5M Sell
307,818
-44,298
-13% -$3.74M 0.02% 653
2017
Q4 		$27.3M Buy
352,116
+44,642
+15% +$3.05M 0.02% 641
2017
Q3 		$18.8M Sell
307,474
-21,561
-7% -$1.14M 0.01% 787
2017
Q2 		$15.1M Buy
329,035
+57,371
+21% +$2.78M 0.01% 895
2017
Q1 		$11.8M Buy
271,664
+39,717
+17% +$1.7M 0.01% 1014
2016
Q4 		$8.98M Buy
231,947
+49,982
+27% +$2.26M 0.01% 1194
2016
Q3 		$9.21M Buy
181,965
+8,775
+5% +$437K 0.01% 1178
2016
Q2 		$7.87M Sell
173,190
-178,008
-51% -$8.2M 0.01% 1218
2016
Q1 		$13.9M Buy
351,198
+24,842
+8% +$986K 0.01% 885
2015
Q4 		$18.5M Buy
326,356
+21,179
+7% +$1.08M 0.01% 785
2015
Q3 		$12.1M Buy
305,177
+13,698
+5% +$662K 0.01% 946
2015
Q2 		$13.9M Buy
291,479
+5,579
+2% +$237K 0.01% 939
2015
Q1 		$11.4M Buy
285,900
+17,523
+7% +$627K 0.01% 1060
2014
Q4 		$6M Sell
268,377
-33,034
-11% -$626K ﹤0.01% 1499
2014
Q3 		$4.72M Sell
301,411
-7,351
-2% -$110K ﹤0.01% 1659
2014
Q2 		$4.58M Buy
308,762
+14,726
+5% +$208K ﹤0.01% 1750
2014
Q1 		$4.73M Buy
294,036
+7,511
+3% +$128K ﹤0.01% 1653
2013
Q4 		$2.68M Hold
286,525
– – ﹤0.01% 2074
2013
Q3 		$3.24M Sell
286,525
-7,318
-2% -$101K ﹤0.01% 1900
2013
Q2 		$3.93M Buy
+293,843
New +$3.61M ﹤0.01% 1695

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TIAA CREF Investment Management's NBIX Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Neurocrine Biosciences (NBIX) stake by 127% in Q1 2019, buying an estimated $24.5M and bringing the position to 524,465 shares worth $46.2M. The position accounts for 0.03% of the portfolio, ranked #427.

TIAA CREF Investment Management first reported a position in NBIX in Q2 2013 and has held it in 24 quarters since. 326 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • TIAA CREF Investment Management held 524,465 shares of Neurocrine Biosciences worth $46.2M as of Q1 2019.
  • TIAA CREF Investment Management bought 293,210 Neurocrine Biosciences shares in Q1 2019, an estimated $24.5M.
  • Neurocrine Biosciences made up 0.03% of TIAA CREF Investment Management's portfolio in Q1 2019, its #427 holding.
  • TIAA CREF Investment Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 24 quarters since.
  • 326 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.